463 related articles for article (PubMed ID: 38204162)
1. The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M; Zhang M; Hussain A; Yu X; Huang J; Huang Y
Mol Ther; 2024 Feb; 32(2):284-312. PubMed ID: 38204162
[TBL] [Abstract][Full Text] [Related]
2. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
3. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
Kulkarni JA; Cullis PR; van der Meel R
Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
[TBL] [Abstract][Full Text] [Related]
4. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Engineering Carriers for siRNA Delivery.
Yang C; Lin ZI; Zhang X; Xu Z; Xu G; Wang YM; Tsai TH; Cheng PW; Law WC; Yong KT; Chen CK
Macromol Biosci; 2024 Apr; 24(4):e2300362. PubMed ID: 38150293
[TBL] [Abstract][Full Text] [Related]
6. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
7. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
8. Strategies, design, and chemistry in siRNA delivery systems.
Dong Y; Siegwart DJ; Anderson DG
Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
[TBL] [Abstract][Full Text] [Related]
9. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
10. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
Yonezawa S; Koide H; Asai T
Adv Drug Deliv Rev; 2020; 154-155():64-78. PubMed ID: 32768564
[TBL] [Abstract][Full Text] [Related]
12. Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies.
Gabel M; Knauss A; Fischer D; Neurath MF; Weigmann B
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430411
[TBL] [Abstract][Full Text] [Related]
13. APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.
Niemietz C; Nadzemova O; Zibert A; Schmidt HH
Amyloid; 2020 Mar; 27(1):45-51. PubMed ID: 31648569
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
Wan C; Allen TM; Cullis PR
Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
[TBL] [Abstract][Full Text] [Related]
15. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.
Gujrati M; Malamas A; Shin T; Jin E; Sun Y; Lu ZR
Mol Pharm; 2014 Aug; 11(8):2734-44. PubMed ID: 25020033
[TBL] [Abstract][Full Text] [Related]
17. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
Ranasinghe P; Addison ML; Dear JW; Webb DJ
Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
[TBL] [Abstract][Full Text] [Related]
18. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.
Pittella F; Zhang M; Lee Y; Kim HJ; Tockary T; Osada K; Ishii T; Miyata K; Nishiyama N; Kataoka K
Biomaterials; 2011 Apr; 32(11):3106-14. PubMed ID: 21272932
[TBL] [Abstract][Full Text] [Related]
19. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.
Sajid MI; Moazzam M; Kato S; Yeseom Cho K; Tiwari RK
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33036435
[TBL] [Abstract][Full Text] [Related]
20. The growth of siRNA-based therapeutics: Updated clinical studies.
Zhang MM; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Biochem Pharmacol; 2021 Jul; 189():114432. PubMed ID: 33513339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
